Drugs that contain Quizartinib Dihydrochloride
1. Vanflyta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8883783 | DAIICHI SANKYO INC | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
Mar, 2027
(2 years from now) | |
| US7820657 | DAIICHI SANKYO INC | Imidazolothiazole compounds for the treatment of disease |
Sep, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8129374 | DAIICHI SANKYO INC | Method of using imidazolothiazole compounds for the treatment of disease |
Mar, 2027
(2 years from now) | |
| US9585892 | DAIICHI SANKYO INC | Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith |
Mar, 2027
(2 years from now) | |
| US8557810 | DAIICHI SANKYO INC | Imidazolothiazole compounds for the treatment of disease |
Mar, 2027
(2 years from now) | |
| US7968543 | DAIICHI SANKYO INC | Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
Aug, 2029
(5 years from now) | |
| US8865710 | DAIICHI SANKYO INC | Methods of treating proliferative diseases |
Aug, 2029
(5 years from now) | |
| US8836218 | DAIICHI SANKYO INC | Methods of treatment using combination therapy |
Mar, 2030
(5 years from now) | |
| US9555040 | DAIICHI SANKYO INC | Methods of treating proliferative diseases |
May, 2030
(6 years from now) | |
| US8357690 | DAIICHI SANKYO INC | Methods of treatment using combination therapy |
Feb, 2031
(6 years from now) | |
| US9675549 | DAIICHI SANKYO INC | Tablet containing composite with cyclodextrin |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-437) | Jul 20, 2030 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2028 |
NCE-1 date: 21 July, 2027
Market Authorisation Date: 20 July, 2023
Treatment: Combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for adult patients with newly diagno...
Dosage: TABLET;ORAL
More Information on Dosage
VANFLYTA family patents
